Clarivate (CLVT)
NYSE:CLVT
Want to see CLVT full AI Analyst Report?
Top Page
Clarivate
(NYSE:CLVT)
Select Model
Select Model
Rating:55Neutral
Price Target:
$2.50
▼(-6.72% Downside)
Action:ReiteratedDate:04/29/26
The score is driven mainly by improving operating performance and solid free cash flow alongside reaffirmed guidance for margin expansion and deleveraging. Offsetting these positives are continued net losses, steep trailing revenue decline, and cautious/neutral technicals with weak valuation support due to a negative P/E and no dividend.
Positive Factors
High recurring revenue mix
Clarivate's shift to subscription-led revenues (recurring mix ~88–90% with subscription organic growth ~1.7%) creates durable cash visibility and lower revenue volatility. Higher renewal rates and a rising ACV base support predictable cash flows that sustain investment, margin expansion, and deleveraging over multiple quarters.
Negative Factors
Modest organic growth
Underlying organic growth remains low (ACV ~1.6%), limiting the company's ability to scale revenue quickly. Slow top-line momentum constrains long-term revenue optionality, makes margin improvements more reliant on cost cuts and disposals, and reduces the runway for compounding returns from new product adoption.
Read all positive and negative factors
Positive Factors
Negative Factors
High recurring revenue mix
Clarivate's shift to subscription-led revenues (recurring mix ~88–90% with subscription organic growth ~1.7%) creates durable cash visibility and lower revenue volatility. Higher renewal rates and a rising ACV base support predictable cash flows that sustain investment, margin expansion, and deleveraging over multiple quarters.
Read all positive factors
Clarivate (CLVT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.78B
Dividend YieldN/A
Average Volume (3M)5.54M
Price to Earnings (P/E)―
Beta (1Y)1.02
Revenue Growth-3.25%
EPS Growth78.91%
CountryUS
Employees12,000
SectorTechnology
Sector Strength88
IndustryInformation Technology Services
Share Statistics
EPS (TTM)-0.21
Shares Outstanding639,216,500
10 Day Avg. Volume6,775,614
30 Day Avg. Volume5,535,747
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)0.46
Price to Sales (P/S)0.92
P/FCF Ratio6.16
Enterprise Value/Market Cap3.30
Enterprise Value/Revenue2.41
Enterprise Value/Gross Profit3.61
Enterprise Value/Ebitda6.70
Forecast
1Y Price Target
$3.46Price Target Upside29.10% Upside
Rating ConsensusHold
Number of Analyst Covering6
EPS Forecast (FY)0.74
Revenue Forecast (FY)$2.36B
Clarivate Business Overview & Revenue Model
Company Description
Clarivate Plc, an information services and analytics company, provides structured information and analytics for discovery, protection, and commercialization of scientific research, innovations, and brands. It offers Web of Science products and ser...
How the Company Makes Money
Clarivate primarily makes money by selling access to its proprietary datasets, analytics, and workflow software through recurring subscriptions (often sold as annual contracts) to institutions and enterprises. A major revenue stream is recurring s...
Clarivate Earnings Call Summary
Earnings Call Date:Apr 29, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Jul 30, 2026
Earnings Call Sentiment Neutral
The call presented a mix of constructive operational and financial progress alongside material near-term headwinds. Highlights include margin expansion (adjusted EBITDA margin up ~200 bps to 41%), improved subscription mix (roughly 88%–89%), strengthened renewal discipline (+100 bps), AI-driven product adoption and efficiency gains, debt reduction actions and a reaffirmed full-year guidance with anticipated free cash flow growth to ~$400M. Offsetting these positives are modest organic growth rates (organic ACV 1.6%), Q1 free cash flow down $31M, transactional revenue softness, planned revenue reductions from disposals (~$100–130M), first-half timing pressure in patent renewals, and a potentially large cash tax increase disclosed in the call, which introduces meaningful near-term cash risk and uncertainty. Overall, the improvement trajectory and margin/cash generation outlook are encouraging, but the modest growth rates and several notable risks keep the picture balanced.Positive Updates
Quarterly Revenue
Q1 revenue of $586 million, supported by continued VCP progress and favorable FX; management reaffirmed full-year revenue guidance (midpoint revenue expected ~$2.36 billion after planned disposals).
Negative Updates
Net Loss and Free Cash Flow Decline in Q1
Q1 net loss of $40 million (improved versus prior year), and free cash flow declined by $31 million versus prior year (Q1 FCF approx. $79M, down ~28% YoY), primarily due to higher working capital from incentive compensation payments.
Read all updates
Q1-2026 Updates
Positive
Negative
Quarterly Revenue
Q1 revenue of $586 million, supported by continued VCP progress and favorable FX; management reaffirmed full-year revenue guidance (midpoint revenue expected ~$2.36 billion after planned disposals).
Read all positive updates
Company Guidance
Clarivate reaffirmed its full-year guidance, forecasting organic ACV growth of 2%–3% (about +0.75 percentage points at the midpoint versus last year) with recurring organic revenue growth near 1.5% at the midpoint and overall organic growth about 1%; revenue is expected to decline to roughly $2.36 billion at the midpoint (about a $100M midpoint decline, with inorganic disposals reducing revenue by roughly $130M), while recurring organic revenue mix should improve to 88%–90%. They expect adjusted EBITDA to expand roughly 200 basis points to nearly a 43% margin at the midpoint and project adjusted diluted EPS of about $0.75 (≈+9% at the midpoint). Free cash flow is guided to roughly $400M (≈+10% or +$35M at the midpoint), with more than $1B of adjusted EBITDA converting to about $400M of FCF, an expected FX translation tailwind of ~$10M to revenue and ~$5M to EBITDA, cash interest improvement of ~ $20M, a working-capital use of ~$20M, a ~$10M paired-contract benefit, and ~$15M lower capex from disposals; the company expects to continue deleveraging (net leverage down from ~4.0x at Q1 to ~2.5x over a few years) and to redeploy FCF toward bond retirements.Clarivate Financial Statement Overview
Summary
Income Statement
46
Neutral
Balance Sheet
58
Neutral
Cash Flow
63
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.45B | 2.46B | 2.56B | 2.63B | 2.66B | 1.88B |
| Gross Profit | 1.63B | 1.62B | 1.69B | 1.72B | 1.71B | 1.25B |
| EBITDA | 878.30M | 828.70M | 456.60M | -10.50M | -3.01B | 532.15M |
| Net Income | -137.40M | -201.10M | -636.70M | -911.20M | -3.96B | -270.50M |
Balance Sheet | ||||||
| Total Assets | 10.93B | 11.07B | 11.49B | 12.71B | 13.94B | 20.18B |
| Cash, Cash Equivalents and Short-Term Investments | 232.30M | 329.20M | 295.20M | 370.70M | 348.80M | 587.61M |
| Total Debt | 4.33B | 4.48B | 4.59B | 4.81B | 5.10B | 5.61B |
| Total Liabilities | 6.14B | 6.23B | 6.35B | 6.71B | 7.13B | 8.26B |
| Stockholders Equity | 4.79B | 4.84B | 5.14B | 5.99B | 6.81B | 11.93B |
Cash Flow | ||||||
| Free Cash Flow | 597.10M | 365.30M | 357.50M | 501.70M | 306.40M | 205.30M |
| Operating Cash Flow | 592.00M | 628.50M | 646.60M | 744.20M | 509.30M | 323.80M |
| Investing Cash Flow | -258.10M | -263.20M | -236.70M | -237.40M | 57.30M | -4.04B |
| Financing Cash Flow | -448.80M | -343.10M | -470.10M | -496.50M | -759.20M | 4.03B |
Clarivate Technical Analysis
Neutral
2.68
Price Trends
2.33
Positive
2.81
Negative
3.39
Negative
Market Momentum
0.02
Negative
60.33
Neutral
83.07
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLVT, the sentiment is Neutral. The current price of 2.68 is above the 20-day moving average (MA) of 2.44, above the 50-day MA of 2.33, and below the 200-day MA of 3.39, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 60.33 is Neutral, neither overbought nor oversold. The STOCH value of 83.07 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CLVT.
Clarivate Risk Analysis
Clarivate disclosed 44 risk factors in its most recent earnings report. Clarivate reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Clarivate Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | $4.85B | 17.71 | 27.16% | ― | 13.35% | 18.39% | |
73 Outperform | $5.83B | 14.72 | 21.81% | 1.41% | 6.60% | 10.28% | |
71 Outperform | $24.84B | 11.05 | 14.79% | 1.46% | 6.55% | -3.10% | |
68 Neutral | $5.93B | 30.32 | 10.27% | ― | 15.42% | -14.70% | |
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
61 Neutral | $9.88B | 24.91 | 74.65% | ― | 3.67% | -40.00% | |
55 Neutral | $1.78B | -10.08 | -2.81% | ― | -3.25% | 78.91% |
* Technology Sector Average
CLVT
Clarivate
2.79
-1.49
-34.81%
CTSH
Cognizant
52.43
-24.11
-31.50%
EPAM
Epam Systems
112.33
-46.79
-29.41%
EXLS
Exlservice Holdings
31.74
-14.80
-31.80%
IT
Gartner
146.40
-280.58
-65.71%
G
Genpact
34.33
-14.43
-29.59%
Clarivate Corporate Events
Business Operations and StrategyFinancial Disclosures
Clarivate Reports Q1 2026 Results, Reaffirms 2026 Outlook
Positive
Apr 29, 2026
On April 29, 2026, Clarivate reported first‑quarter 2026 results showing total revenue of $585.5 million, down 1.4% year on year due to disposals, but with 0.6% organic growth and a 1.6% rise in organic ACV, as subscription revenues grew 1.7...
Business Operations and StrategyExecutive/Board Changes
Clarivate Updates Executive Severance Plan and Equity Vesting
Neutral
Mar 26, 2026
On March 23, 2026, Clarivate’s board approved an Amended and Restated Executive Severance Plan, updating the executive protections originally put in place on June 30, 2021. The plan continues to cover members of the Executive Leadership Team...
Business Operations and StrategyStock BuybackFinancial DisclosuresM&A Transactions
Clarivate Advances Subscription Model, Explores Life Sciences Divestiture
Positive
Feb 24, 2026
On February 24, 2026, Clarivate reported fourth-quarter and full-year 2025 results showing lower reported revenue due to divestitures but improving quality of earnings, with organic ACV up 1.8%, recurring organic revenue growing and the mix of rec...
Business Operations and StrategyRegulatory Filings and Compliance
Clarivate Shares AI-Focused Intelligence Webinar With Investors
Neutral
Feb 3, 2026
On February 3, 2026, Clarivate made available on the investor relations section of its website a video webinar titled “Intelligence Amplified in the Age of AI,” along with related presentation materials, as part of its communications t...
Business Operations and StrategyStock Buyback
Clarivate redeems notes, advances capital allocation strategy
Positive
Feb 2, 2026
On January 30, 2026, Clarivate’s subsidiary Camelot Finance S.A. fully redeemed the remaining $100 million principal amount of its 4.50% senior secured notes due 2026 at par plus accrued interest, funded with cash on hand, and subsequently s...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.